Clinical trial
A Single Arm, Open Label, Multiple Center, Prospective Study of Disitamab Vedotin Combined With Tislelizumab in HER2 Positive Advanced Colorectal Cancer Failed at Least Two Lines of Systemic Treatment.
NCT05493683 is registered in ClinicalTrials.gov with The First Affiliated Hospital with Nanjing Medical University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single Arm, Open Label, Multiple Center, Prospective Study of Disitamab Vedotin Combined With Tislelizumab in HER2 Positive Advanced Colorectal Cancer Failed at Least Two Lines of Systemic Treatment.
- Lead sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- August 1, 2022
- Completion date
- July 31, 2025
- Enrollment
- 29 (estimated)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.